Clinical trial

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

NCT03737708

Study summary

ClinicalTrials.gov

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record tacrolimus Normalized identity: tacrolimus View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record methotrexate Normalized identity: methotrexate View linked drug · Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention adalimumab Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention tocilizumab Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention abatacept Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-02-13

PhasePHASE4

Conditions

Rheumatoid Arthritis (RA)unresolved

Interventions

tacrolimusDRUG · verified · RxNorm: tacrolimus

methotrexateDRUG · verified · RxNorm: methotrexate

adalimumabBIOLOGICAL

tocilizumabBIOLOGICAL

abataceptBIOLOGICAL

Sponsors & collaborators

Astellas Pharma Korea, Inc.lead sponsor

Mapped research locations

SeoulSouth Korea4 DaeguSouth Korea2 IncheonSouth Korea1 SuwonSouth Korea1 DaejeonSouth Korea1 SeongnamSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03737708 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.